Scripps Research Logo

Welcome to the Rosen Laboratory Website!


October 12, 2015

The Molecular Libraries and Imaging Program Continues to Pay Dividends

After Leaving the Common Fund

The Common Fund’s Molecular Libraries and Imaging (MLI) Program has made promising inroads in the development of new therapeutics for human disease. A compound initially discovered by the NIH Molecular Libraries Probe Production Center at The Scripps Research Institute (TSRI), which was a part of the MLI program, was a precursor to the drug candidate ozanimod; which is currently in two Phase III clinical trials –one for patients with relapsing multiple sclerosis and the other in patients with ulcerative colitis. Dr. Hugh Rosen, a professor at TSRI was a Center Principal Investigator...CLICK HERE TO READ ON

NRDD Article

Additional Information on Ozanimod (RPC1063)

Receptos Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis


Comprehensive Center for Chemical Probe Discovery and Optimization at TSRI